Synapse Open Synapse
Biology

Lilly, Foghorn part ways; Wave’s FDA-approved plans

BioPharma Dive · · 2 min read

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

Latest from BioPharma Dive